ApoB is one piece of the picture

Most people who follow this space have heard of ApoB by now, and that's a good thing. It counts the particles that can get into the artery wall, which makes it a better read on risk than LDL cholesterol for a lot of people. The trouble is when it becomes the whole conversation, since ApoB only answers one question, which is how much traffic is on the road. The fuller picture has a few more pieces. Lp(a) is a particle that's mostly set by your genes, raises heart attack and stroke risk on its own, and isn't on a standard lipid panel, so a lot of people with a high level never find out. Lp-PLA2 is an enzyme that tracks inflammation inside the artery wall, and a higher level points to plaque that's more active and more likely to cause a problem. Then imaging, like a coronary calcium score or a CT angiogram, shows what has actually built up so far. Each one answers a different question. ApoB is how much is getting in, Lp(a) is how much of the risk you were born with, Lp-PLA2 is how active things are right now, and imaging is what's already there. When I see someone with a normal lipid panel and one of these clearly off, it changes how seriously the whole plan gets taken, which is the point of looking at them together. One caveat on Lp-PLA2, drugs that lowered it didn't reduce heart attacks in trials, so I treat it as a warning light rather than a target.